[go: up one dir, main page]

WO1998014567A3 - Methods and compositions for inhibiting bacterial growth - Google Patents

Methods and compositions for inhibiting bacterial growth Download PDF

Info

Publication number
WO1998014567A3
WO1998014567A3 PCT/US1997/018094 US9718094W WO9814567A3 WO 1998014567 A3 WO1998014567 A3 WO 1998014567A3 US 9718094 W US9718094 W US 9718094W WO 9814567 A3 WO9814567 A3 WO 9814567A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
bacterial growth
inhibiting bacterial
bacterial infection
Prior art date
Application number
PCT/US1997/018094
Other languages
French (fr)
Other versions
WO1998014567A2 (en
Inventor
William J Martin
Paul Wisniowski
Original Assignee
William J Martin
Paul Wisniowski
Advanced Res & Tech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William J Martin, Paul Wisniowski, Advanced Res & Tech Inst filed Critical William J Martin
Priority to AU46720/97A priority Critical patent/AU4672097A/en
Publication of WO1998014567A2 publication Critical patent/WO1998014567A2/en
Publication of WO1998014567A3 publication Critical patent/WO1998014567A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates generally to the field of bacteriology. More particularly, it concerns methods and compositions for the treatment of bacterial infection employing oligonucleotides targeted to the Shine-Dalgarno region of prokaryotes to inhibit bacterial protein expression and hence inhibit bacterial infection.
PCT/US1997/018094 1996-10-01 1997-09-30 Methods and compositions for inhibiting bacterial growth WO1998014567A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46720/97A AU4672097A (en) 1996-10-01 1997-09-30 Methods and compositions for inhibiting bacterial growth

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2772996P 1996-10-01 1996-10-01
US60/027,729 1996-10-01

Publications (2)

Publication Number Publication Date
WO1998014567A2 WO1998014567A2 (en) 1998-04-09
WO1998014567A3 true WO1998014567A3 (en) 1998-07-16

Family

ID=21839436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018094 WO1998014567A2 (en) 1996-10-01 1997-09-30 Methods and compositions for inhibiting bacterial growth

Country Status (2)

Country Link
AU (1) AU4672097A (en)
WO (1) WO1998014567A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319497B1 (en) * 1997-04-23 2001-11-20 Virginia Tech Intellectual Properties, Inc. Non-obligate predatory bacterium burkholderia casidaeand uses thereof
RU2224524C2 (en) * 2002-03-29 2004-02-27 Некоммерческое партнерство "АСГЛ - Исследовательские лаборатории" Oligonucleotides for suppression of pathogenic microorganisms vital activity and method for suppression of their vital activity
JP2004313181A (en) 2003-04-02 2004-11-11 Canon Inc Probe and probe set for detecting causative bacteria of infectious disease, carrier and gene testing method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0140308A2 (en) * 1983-10-20 1985-05-08 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition utilizing mRNA interfering complementary RNA
WO1990000624A1 (en) * 1988-07-05 1990-01-25 Baylor College Of Medecine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
WO1993023570A1 (en) * 1992-05-11 1993-11-25 Pharmagenics, Inc. Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety
WO1995027054A1 (en) * 1994-03-30 1995-10-12 Universite De Montreal Use of dna oligomers for inhibition of hiv by decreasing ribosomal frameshifting
WO1996024378A2 (en) * 1995-02-10 1996-08-15 Worcester Foundation For Biomedical Research, Inc. Delivery of exogenous compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0140308A2 (en) * 1983-10-20 1985-05-08 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition utilizing mRNA interfering complementary RNA
WO1990000624A1 (en) * 1988-07-05 1990-01-25 Baylor College Of Medecine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
WO1993023570A1 (en) * 1992-05-11 1993-11-25 Pharmagenics, Inc. Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety
WO1995027054A1 (en) * 1994-03-30 1995-10-12 Universite De Montreal Use of dna oligomers for inhibition of hiv by decreasing ribosomal frameshifting
WO1996024378A2 (en) * 1995-02-10 1996-08-15 Worcester Foundation For Biomedical Research, Inc. Delivery of exogenous compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JAYARAMAN K ET AL: "SELECTIVE INHIBITION OF ESCHERICHIA COLI PROTEIN SYNTHESIS AND GROWTH BY NONIONIC OLIGONUCLEOTIDES COMPLEMENTARY TO THE 3' END OF 16S RRNA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 78, no. 3, March 1981 (1981-03-01), pages 1537 - 1541, XP002045889 *
RAHMAN M A ET AL: "ANTIBACTERIAL ACTIVITY AND INHIBITION OF PROTEIN SYNTHESIS IN ESCHERICHIA COLI BY ANTISENSE DNA ANALOGS", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 1, 1991, pages 319 - 327, XP002045888 *
TANIGUCHI, T. & WEISSMANN, C.: "Inhibition of Qbeta RNA 70S ribosome intiation complex formation by an oligonucleotide complementary to the 3' terminal region of E.coli 16S ribosomal RNA", NATURE., vol. 275, 26 October 1978 (1978-10-26), LONDON GB, pages 770 - 772, XP002055331 *
THIERRY A R ET AL: "LIPOSOMAL DELIVERY AS A NEW APPROACH TO TRANSPORT ANTISENSE OLIGONUCLEOTIDES", GENE REGULATION, BIOLOGY OF ANTISENSE RNA AND DNA, 1992, ERICKSON R P;IZANT J G, pages 147 - 161, XP002040368 *
TOSCHKA, H. ET AL.: "Complete nucleotide sequence of a 16S ribosomal RNA from Pseudomonas aeruginosa", NUCLEIC ACIDS RESEARCH., vol. 16, 1988, OXFORD GB, pages 2348, XP002055330 *

Also Published As

Publication number Publication date
AU4672097A (en) 1998-04-24
WO1998014567A2 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
WO2000034265A3 (en) Quinoline-indole antimicrobial agents
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
WO2001098362A3 (en) Chemically-modified antimicrobial peptides, compositions and methods of production and use
WO2003099110A3 (en) Herbs and herbal combinations useful for the treatment of microbial infections
AU6549898A (en) Method for the broad based treatment of infections, especially infections of organs such as the skin and vagina
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
HK1049656A1 (en) Fab i inhibitors
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
WO1996040768A3 (en) Anti-fungal and anti-bacterial histatin-based peptides
ZA200108215B (en) Compositions and methods for treatment of staphylococcal infection.
WO2005019241A3 (en) Cationic antimicrobial peptides and compositions thereof
EP1015011A4 (en) Peptide nucleic acids having antibacterial activity
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
ZA200108912B (en) Attenuated microorganisms for the treatment of infection.
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
PT932613E (en) EXPRESSION OF BLOCKING VIRULENCE FACTS IN S. AUREUS
WO1999067238A3 (en) Tetrahydroquinoline-indole derivatives antimicrobial agents, their uses and compositions containing them
WO2002005642A3 (en) Synergistic biocidal compositions
DE69914911D1 (en) PHARMACEUTICAL PREPARATIONS FOR CONTROLLING OR PROPHYLAXIS OF SURFACES INFECTED BY MICRO-ORGANISMS
EP0943311A3 (en) Method of inhibiting hair growth
MXPA00007394A (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases.
WO2003009859A1 (en) Immunotherapy for humans
WO1998014567A3 (en) Methods and compositions for inhibiting bacterial growth
AU1261601A (en) Treatment of C. difficile toxin B associated conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998516970

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase